Competing Risks Model in Screening for Preeclampsia by Serum Placental Growth Factor and Soluble fms-Like Tyrosine Kinase-1 at 30-33 Weeks' Gestation

Publisher： Karger

E-ISSN： 1421-9964|35|4|240-248

ISSN： 1015-3837

Source： Fetal Diagnosis and Therapy, Vol.35, Iss.4, 2014-05, pp. : 240-248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Competing Risks Model in Screening for Preeclampsia by Biophysical and Biochemical Markers at 30-33 Weeks' Gestation

By  

Fetal Diagnosis and Therapy, Vol. 36, Iss. 1, 2014-05 ,pp. : 9-17

Karger

Access to resources Recommend Favorite

Competing Risk Model in Screening for Preeclampsia by Mean Arterial Pressure and Uterine Artery Pulsatility Index at 30-33 Weeks' Gestation

By  

Fetal Diagnosis and Therapy, Vol. 36, Iss. 1, 2014-06 ,pp. : 18-27

Karger

Access to resources Recommend Favorite

Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia

By  

Fetal Diagnosis and Therapy, Vol. 33, Iss. 3, 2013-02 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8–13 Weeks’ Gestation

By  

Fetal Diagnosis and Therapy, Vol. 31, Iss. 2, 2012-01 ,pp. : 87-93

Karger

Access to resources Recommend Favorite

Maternal Serum Placental Growth Factor Isoforms 1 and 2 at 11-13, 20-24 and 30-34 Weeks' Gestation in Late-Onset Pre-Eclampsia and Small for Gestational Age Neonates

By  

Fetal Diagnosis and Therapy, Vol. 35, Iss. 4, 2014-03 ,pp. : 249-257

Karger

Access to resources Recommend Favorite